Leveraging its proprietary technology platforms, Alphamab Oncology has developed a highly differentiated pipeline of novel drug candidates, including single domain antibodies, bispecific antibodies, and BADCs. Envafolimab (KN035), the world's first subcutaneously injected PD-L1 inhibitor, has received market approval, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for Anbenitamab (KN026), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Five bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines, such as dual-payload ADCs, are advancing rapidly. Two programs were recognized by China’s “New Drug Development” initiative, four products had collectively received six FDA Orphan Drug Designations (ODD), one product was granted Breakthrough Therapy Designation (BTD) by the FDA, and three products were granted four BTDs by the NMPA.
